X-37
X37 is a drug development company that leverages AI technology to work on difficult-to-target proteins, focusing on targets of high therapeutic value in autoimmune disease, cancer, and anticoagulation. They aim to accelerate drug discovery by building partnerships with AI companies and using cutting-edge technology to identify small molecules for challenging targets.
Industries
artificial-intelligence
health-care
pharmaceutical
Nr. of Employees
small (1-50)
Services
Collaborative AI-enabled small-molecule discovery
Collaborative discovery model that leverages partnerships with AI technology providers to identify and prioritize small-molecule binders for challenging targets.
Collaborative AI-enabled small-molecule discovery
Collaborative discovery model that leverages partnerships with AI technology providers to identify and prioritize small-molecule binders for challenging targets.
Expertise Areas
- AI-driven drug discovery
- Small-molecule discovery
- Difficult-to-drug target discovery
- Oncology drug discovery
Key Technologies
- AI / machine learning for drug discovery
- In silico small-molecule identification
- Computational chemical space exploration
- Virtual screening